- Home
- TCBS vs MAIA Comparison
TCBS vs MAIA Comparison
Compare TCBS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- MAIA
- Stock Information
- Founded
- TCBS 1934
- MAIA 2018
- Country
- TCBS United States
- MAIA United States
- Employees
- TCBS N/A
- MAIA N/A
- Industry
- TCBS Banks
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- MAIA Health Care
- Exchange
- TCBS Nasdaq
- MAIA Nasdaq
- Market Cap
- TCBS 44.9M
- MAIA 46.7M
- IPO Year
- TCBS N/A
- MAIA 2022
- Fundamental
- Price
- TCBS $15.75
- MAIA $1.79
- Analyst Decision
- TCBS
- MAIA
- Analyst Count
- TCBS 0
- MAIA 0
- Target Price
- TCBS N/A
- MAIA N/A
- AVG Volume (30 Days)
- TCBS 3.5K
- MAIA 274.6K
- Earning Date
- TCBS 06-10-2025
- MAIA 05-09-2025
- Dividend Yield
- TCBS 1.02%
- MAIA N/A
- EPS Growth
- TCBS N/A
- MAIA N/A
- EPS
- TCBS 0.68
- MAIA N/A
- Revenue
- TCBS $14,488,000.00
- MAIA N/A
- Revenue This Year
- TCBS N/A
- MAIA N/A
- Revenue Next Year
- TCBS N/A
- MAIA N/A
- P/E Ratio
- TCBS $23.15
- MAIA N/A
- Revenue Growth
- TCBS 54.08
- MAIA N/A
- 52 Week Low
- TCBS $13.51
- MAIA $1.40
- 52 Week High
- TCBS $17.50
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- TCBS 54.51
- MAIA 47.79
- Support Level
- TCBS $15.50
- MAIA $1.71
- Resistance Level
- TCBS $15.58
- MAIA $1.85
- Average True Range (ATR)
- TCBS 0.05
- MAIA 0.13
- MACD
- TCBS 0.03
- MAIA -0.02
- Stochastic Oscillator
- TCBS 62.50
- MAIA 25.64
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.